Galderma (BX:GALD) Added to SMI; Raises 2026 Sales Growth Guide
Galderma joined the Swiss Market Index and raised its 2026 net sales growth guidance to 19—21% at constant currency, from 17—20%, while reaffirming a Core EBITDA margin of approximately 26% at constant currency.Material DetailsContext by AI AnalystThis is a mid-cycle confirmation of accelerating gr…
Story updates
05:15:57 AM UTC
SquawkNews
Galderma Group AG (SIX:GALD) reported H1 2026 sales up 24.6% YoY (cc), raised 2026 sales-growth guidance to 19—21% and reaffirmed ~26% Core EBITDA margin (cc), while Restylane Volyme trials showed durable temple improvements, high satisfaction/recommendation rates and strong safety with rapid socia…